High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission

Bone Marrow Transplantation

Volumn 41, Issue 8, 2008, Pages 721-727

  Schmid, C ^a,b   Schleuning, M ^c   Hentrich, M ^d   Markl, G E ^a   Gerbitz, A ^a,e   Tischer, J ^a   Ledderose, G ^a   Oruzio, D ^b   Hiddemann, W ^a   Kolb, H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d Klinikum Harlaching   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DISEASE; HIGH RISK PATIENT; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KARYOTYPE; KIDNEY DISEASE; LEUKEMIA REMISSION; LIVER DISEASE; LOW DRUG DOSE; LUNG DISEASE; MALE; MOUTH INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; REDUCED INTENSITY CONDITIONING; SEPTIC SHOCK; SIBLING; SURVIVAL RATE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; CASE-CONTROL STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 42649131744     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705965     Document Type: Article

References (37)

1. Lowenberg B, Downing J, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Byrd JC, Mrozek K, Dodge RK, Carrol AJ, Edwards CG, Arthur DC et al Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
5. Wheatle K, Burnett A, Goldstone A, Gray RG, Hann I, Harrison G et al A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999; 107: 69-79.
6. Kern W. Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction chemotherapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
7. Appelbaum FR. Who should be transplanted for AML. Leukemia 2001; 15: 680-682.
8. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1092 patients with de novo AML. Leukemia 2004; 18: 120-125.
9. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-208.
10. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 646-655.
11. Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L. Prognostic factors of patients with acute myeloid leukemia allografted in first CR: An analysis of the EORTC/GIMEMA AML 8A trial. Bone Marrow Transplant 1996; 17: 993-1001.
12. Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134-2141.
13. Martino R, Caballero MD, Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
14. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480-1484.
15. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102 3052-3059.
16. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003; 21: 3060-3065.
17. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
18. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A et al. Conditioning with 8Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005; 106: 3314-3321.
19. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
20. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
21. Schlenk RF, Brenner A, Krauter J, Büchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750.
22. Chason B. Revised criteria of the international working group for diagnostics, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
23. Sorror ML, Maris M, Storb R, Baron F, Sandmaier BM, Maloney D et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
24. Sullivan KM. Graft-versus-host-disease. In: Thomas E, Blume K, Forman SJ(eds). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science: Boston, 1999, pp 515-536. Ref Type: Serial (Book, Monograph).
25. Durnam DM, Anders KR, Fisher L, O'Quigley J, Bryant EM, Thomas ED. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 1989; 74: 2220-2226.
26. Anslinger K, Rolf B, Keil W. Evaluation and application of the AmpF/STR profiler plus PCR amplification kit in a Bavarian population sample. Int J Legal Med 2001; 114: 278-280.
27. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Bone Marrow Transplantation Study. Blood 1997; 90: 2931-2938.
28. Cornelissen JJ, Van Putten W, Verdonck L, Theobald M, Jacky E, Daenen SMG et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
29. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
30. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
31. Van Besien K, Smith AS, Cao D, Rich S, Godley L, Jones D et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728-5738.
32. Blaise D, Boiron JM, Faucher C, Mohty MBJO, Bardoux V, Perreau V et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with AML as first-line treatment. Cancer 2005; 104: 1931-1938.
33. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
34. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
35. Aoudjhane M, Labopin M, Gorin N, Shimoni A, Ruutu T, Kolb H-J. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
36. Scott B, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG. Myeloablative versus nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006; 20: 128-135.
37. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Avigdor A, Ben-Bassat I et al. Allogeneic haematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.